Crossmark

CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges

Crossref DOI link: https://doi.org/10.1136/jitc-2024-009793

Published Online: 2025-06-05

Published Print: 2025-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Shune, Leyla

Frigault, Matthew J

Riedell, Peter A
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals Corporation (NA)
License Information

License valid from 2025-06-05